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Abstract 
Background. The outcome of patients with adenocarcinoma of the esophagogastric 
junction (AEG) remains poor. The programmed cell-death-protein-1 (PD-1), a co-
inhibitory receptor primarily expressed by T-cells, represents a potential new 
therapeutic target. PD-1, PD-1 ligand 1 (PD-L1), and PD-L2 expression have all been 
described as prognostic factors in a variety of cancers. Their expression patterns in 
AEG, however, are poorly understood. We analyzed PD-L1, PD-L2 and PD-1 
expression by tumor-infiltrating lymphocytes (TILs) and cancer-cells in tumor-
biospecimens in AEG-patients. Methods. 168 patients who underwent 
esophagectomy because of AEG between 1992-2011 were included in this study. PD-
L1, PD-L2 and PD-1 expression were evaluated by immunohistochemistry and 
correlated with various clinicopathological parameters, disease-free survival (DFS) 
and long-term overall survival (OS). Results. PD-L1 expression by cancer-cells 
(cancer-cell-PD-L1+) was found in 43.5% of patients whereas PD-L1 expression by 
TILs (TILs-PD-L1+) was observed in 69%. PD-L2 expression by cancer-cells and TILs 
was only found in 3.5% and 1.8%, respectively. Additionally, 77.4% of tumors 
contained PD-1+-cancer-cells and 81% PD-1+-TILs. Patients with increased 
expression of PD-1 by cancer-cells and TILs showed significantly reduced OS and 
DFS, as determined by univariate, but not multivariate analysis. Expression of PD-L1 
by cancer-cells was found to be an independent predictor for improved DFS (p=0.038) 
and OS (p=0.042) in multivariate analysis. Conclusions. Cancer cells and TILs 
displayed PD-L1 expression in around 50% and PD-1 expression in around 80% of 
tumor-biospecimens obtained from AEG patients. Expression of PD-L1 is an 
independent predictor of favorable outcome in AEG, whereas PD-1 expression is 
associated with worse outcome and advanced tumor stage. 
 
 5 
Key words 
PD-1, PD-L1, PD-L2, esophageal adenocarcinoma, esophageal carcinoma 
 
Financial support 
This study was supported by the Forschungskredit of the University of Zurich (FK-15-
040 to W.H., FK-17-023 to Y.T.C.), the Jubiläumsstiftung von SwissLife (to E. G.), 
Swiss National Science Foundation (PMPDP3_151326 to E.G.), and the 
Hochspezialisierte Medizin Schwerpunkt Immunologie (HSM-2-Immunologie) Schweiz 
as well as an unrestricted research grant provided to the upper-GI-service and 
research, Department of Surgery, Medical University of Vienna. The funders had no 
role in study design, data collection and analysis, decision to publish, or preparation of 
the manuscript.  
 
Disclosure of interest 
The authors report no conflict of interest 
 
  
 6 
Abbreviations 
AEG – adenocarcinoma of the esophagogastric junction 
CI – confidence interval 
DFS – disease free survival 
ESCC – esophageal squamous cell carcinoma 
HR – hazard ratio 
ICH – Immunohistochemistry 
IQR – interquartile range 
NSCLC – non small cell lung cancer 
OS – overall survival 
PD-1 – programmed cell death 1 receptor 
PD-L1 – programmed cell death 1 receptor ligand 1 
PD-L2 – programmed cell death 1 receptor ligand 2 
RT – room temperature 
TILs – tumor infiltrating lymphocytes 
TME – tumor microenvironment 
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Introduction 
The prevalence of esophageal cancer is increasing, and it currently represents the 
eighth most common cancer and sixth most common cause of cancer-related death 
worldwide.1,2 The 5-year overall survival (OS) rates for patients with esophageal 
carcinoma range from 10-15%, with only moderate improvement over the past years. 
3 Eesophageal carcinoma treatment includes surgical resection, as well as cytotoxic 
chemotherapy, radiotherapy, or targeted treatment modalities (e.g. monoclonal 
antibody directed against HER2). 3,4 Therapeutic antibodies targeting the programmed 
cell death 1 (PD-1) pathway have made substantial inroads in the treatment of several 
advanced cancers of various etiology, and may thus also represent an additional 
therapeutic option in AEG patients. 5,6 PD-1 is an immune checkpoint receptor and 
prominent mediator of tumor immune evasion, that is primarily up-regulated by 
activated T cells, including TILs. Multiple tumor entities have been studied for their 
expression of the PD-1 ligands, PD-L1 and PD-L2. 7 Increased PD-1 ligand expression 
in the tumor microenvironment (TME) was reported to be associated with poor 
prognosis in several tumors (e.g. renal cancer, breast cancer, hepatocellular 
carcinoma, and colorectal cancer), consistent with the established role of the PD-1:PD-
1 ligand axis in tumor immune evasion. 8-14 Accordingly, both PD-1 and PD-L1 blocking 
antibodies can activate tumor-specific immune response by overcoming PD-1 
pathway-mediated immune escape. Indeed, excellent results have been reported in 
multiple large-scale clinical trials involving PD-1/PD-L1 blocking antibodies for the 
treatment of advanced solid tumors and hematologic malignancies.15,16,17 To date, 
several studies have investigated the expression pattern of PD-1 and its ligands in 
esophageal squamous cell carcinoma (ESCC). 18-22 However, only limited data is 
available on the PD-1 pathway in esophageal adenocarcinoma. In this study, we aimed 
to further elucidate the role of PD-1, PD-L1 and PD-L2 expression in esophageal 
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adenocarcinoma. Specifically, we systematically examined the prognostic impact of 
PD-L1 and PD-L2 expression by cancer cells and by TILs on DFS and OS in a large 
cohort of patients undergoing esophagectomy for esophageal adenocarcinoma.  
 
  
 9 
Methods 
 
Study population 
Patients undergoing esophageal resection for adenocarcinoma of the esophagogastric 
junction (AEG) between the years 1992 and 2011 (n=168) at the Department of 
Surgery, Medical University of Vienna, were included. Data were collected from the 
institutional database and individual patient charts were reviewed. According to the 
institutional policy, post-surgical follow-up was conducted in three-months intervals 
during the first year after esophagectomy, in six-month intervals during the following 
three years, and yearly thereafter. Histological analyses were performed in a large 
collection of archived tissue samples of resected tumors. Approval for the study has 
been obtained by the local ethical committee of the Medical University of Vienna (# 
1056/2016). 
 
Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) was performed on 3-5 μm thick paraffin sections as 
previously described.23 The sections were deparaffinized and rehydrated in graded 
series: X-TRA-Solv 8 (Medite, # 41-5212-00) - 15 min at 68°C; Xylol – 5 min room 
temperature (RT), 100% EtOH - 5 min RT; 96% EtOH - 5 min RT; 80% EtOH - 5 min 
RT; distilled water - 2 min RT. For antigen retrieval, the slides were heated in a Dako 
Cytomation Pascal Pressure Cooker (115°C) and after that, endogenous peroxidase 
activity was blocked using 3% hydrogen peroxide in distilled water (10 min). Normal 
goat serum was used to block non-specific epitopes (30 min) and after that the sections 
were incubated with the following primary antibodies: mouse anti-human PD1 (R&D 
systems, # AF 1086, dilution 1:20), PD-L1 (Cell signaling, clone: E1L3N, dilution: 1:25), 
PD-L2 (Cell signaling, clone: D7U8C, dilution: 1:25) as well as the corresponding 
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biotinylated anti-goat IgG secondary antibody (1:100 dilution, 30 min). Following 
manufacturer’s protocol (Dako), visualization was achieved via application of 
streptavidin conjugated to alkaline phosphatase. Additional Mayer’s hematoxylin 
staining was applied in order to depict the cell nuclei. 
The tumor samples were investigated blinded to patients’ clinical data on one slide per 
patient. On lower magnification (40x), the pattern and distribution of PD-L1, PD-L2 and 
PD-1 expression over the whole area of the tumor was assessed. In case of 
heterogeneity of the expression patterns within individual tumor lesions, we selected 
four visual fields representing all patterns of levels of PD-L1, PD-L2 and PD-1 
expression present in the studied lesion (x400). PD-L1, PD-L2 and PD1 expression 
was analyzed separately for cancer cells and TILs. The percentage of cancer cells and 
lymphocytes showing immuno-reactivity to PD-L1, PD-L2 and PD-1 was rated (positive 
staining, 0-100%) and classified: 0: no positive cells, 1+: 1-25% of cells, 2+: 26-50% 
of cells, 3+: 51-75% of cells and 4+: 76-100% of cells. Histological analyses were 
performed by three pathologists that were blinded to the clinical characteristics of each 
patient. The slides were independently graded and if the rating differed, the slides were 
re-discussed using a multi-head microscope and a consensus was found. For some 
analysis, expression was divided in PD-L1 negative (PD-L1-) and PD-L1 positive 
(PD1+).  
 
Statistical analysis 
Overall survival (OS) was defined as time between primary surgery and the patient’s 
death. Disease free survival (DFS) was defined as time from primary surgery until first 
evidence of disease-progression. Patients without complete resection (n=23) were 
excluded form the analyses of OS as well as DFS. 
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Median follow up and interquartile range (IQR) of median follow up was estimated by 
reverse Kaplan-Meier method. Kaplan-Meier curves were plotted to investigate 
differences in OS and DFS between PD-L1 expression patterns of cancer cells and 
TILs, respectively.  
Differences in clinicopathological parameter distributions between patients with PD-L1- 
and PD-L1+ expression were assessed by Fisher’s exact test and by its extension for 
>2x2 tables in case of parameters with more than 2 levels. Clinicopathological 
parameters included categorical variables only. 
Univariate Cox proportional hazards models were carried out to estimate the effect of 
PD-L1 and PD-1 expression of cancer cells and of TILs as well as other 
clinicopathological parameters on OS and DFS, separately. Stepwise regression 
analysis was applied to select the set of predictors that best predict OS and DFS, 
respectively, in the setting of a multivariate Cox proportional hazard model. PD-1 
expression by tumor cells and TILs were kept in the model for comparison with 
previous results. Proportional hazard assumptions were assessed visually and tested 
using diagnostics based on weighted residuals. All tests were two-sided and p-values 
less than 0.05 were considered statistically significant. All statistical analyses were 
performed with the statistical software R version 3.33 (R Development Core Team, 
2017). 24 
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Results 
 
Patients’ characteristics  
In total, 168 patients who had undergone esophagectomy for esophageal 
adenocarcinoma between 1992 and 2011 were included in this study. The mean age 
at the time of surgery was 65 years (range 35-88 years, ±10.4 years) and the ratio of 
female to male patients was 31:137. The median follow-up time for OS was 66 months 
(IQR 28-96 months). OS rates of patients with complete resection (n=145) at one, 5 
and 10 years were 78.6% (107 patients at risk), 49.9% (54 patients at risk) and 37.3% 
(12 patients at risk), respectively. The median follow up for DFS reached 61 months 
(IQR 28-96 months). DFS rates at one, 5 and 10 years were calculated as 72.6% (79 
patients at risk), 48.7% (31 patients at risk) and 39.7% (6 patients at risk), respectively. 
Neoadjuvant therapy was applied in 63 patients (37.5%) (neoadjuvant chemotherapy 
(n=59) and neoadjuvant radiochemotherapy (n=4)). Tables 1 and 2 summarize clinical 
and histopathological data.  
 
Expression of PD-L1 in cancer cells and TILs 
PD-L1 expression was determined by IHC and quantitated separately for cancer cells 
and TILs. PD-L1 expression by cancer cells was detected in 73/168 patients (43.5%), 
with PD-L1+ cancer cell frequencies distributed as follows: 0 (0%): n=95 (56.5%), 1+ 
(1-25%): n=51 (30.4%), 2+ (26-50%): n=12 (7.1%), 3+ (51-75%): n=8 (4.8%), 4+ (76-
100%): n=2 (1.2%) (Table 1). Tumor biospecimens from 116/168 patients (69%) 
contained PD-L1+ TILs, categorized as: 0 (0%): n=52 (31%), 1+ (1-25%): n=77 
(45.8%), 2+ (26-50%): n=29 (17.3%), 3+ (51-75%): n=10 (6%) and 4+ (76-100%): n=0 
(0%) (Table 2). Representative images for (a) negative (0) PD-L1 staining on cancer 
cells, (b) 2+ and (c) 3+ positive PD-L1 staining on cancer cells as well as (d) negative 
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(0) PD-L1 staining on TILs (e), 2+, and (f) 4+ positive PD-L1 staining by TILs are 
depicted in Figure 1. 
 
Expression of PD-L2 by cancer cells and by TILs 
PD-L2 expression was evaluated separately for cancer cells and TILs by IHC staining. 
Only 6 patients with esophageal adenocarcinoma (3.6%) showed positive PD-L2 
staining by cancer cells (1+ (1-25%): n=5 (3%) and 2+ (26-50%): n=1 (0.6%)). Two of 
these patients also harbored PD-L1+ cancer cells, and 5 PD-L1+-TILs in the respective 
tumor biospecimens. Furthermore, only 3 tumors (1.8%) were found to contain PD-L2+ 
TILs, all of which were classified as 1+ (1-25%) and also positive for PD-L1 on both 
cancer cells and TILs.  
 
Comparison of tumors with or without PD-L1+ cancer cells  
Patients were separated into 2 groups: those containing PD-L1+ cancer cells (n=73) 
and those negative for cancer cell-PD-L1 (n=95); clinicopathological findings were 
evaluated and compared between both groups (Table 1). Tumors with PD-L1+ cancer 
cells were more likely found during earlier tumor stages compared to patients with 
cancer cell-PD-L1- tumors (p=0.045; pT1a+pT1b: n=21/73 (28.8%) vs. 12/95 (12.6%), 
pT2 14/73 (19.2%) vs. 35/95 (36.8%), respectively, Table 1). However, a similar 
number of patients were classified as pT3 when comparing tumors with and without 
PD-L1+-cancer cells (33/73 (45.2%) vs. 44/95 (46.3%), Table 1). There were no 
significant differences between the two groups in lymph node status (p=0.520), 
histologic grading (p=0.584), or anatomical AEG location (p=0.072), as determined by 
the Siewert classification  (Table 1), and a similar number of patients received 
neoadjuvant therapy in both groups (26/73 (35.6%) vs. 37/95 (39%), p=0.748, Table 
1). PD-1 receptor expression patterns, on the other hand, significantly differed between 
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PD-L1+ and PD-L1--cancer cell groups (p=0.016). For instance, from 38/168 (22.6%) 
patients with tumors negative for cancer cell-PD-1, 63.2% (24/38) nevertheless 
harbored PD-L1+ cancer cells. Similarly, 81 of the 130 patients demonstrating tumorcell 
PD-1 expression (62.3%) did not contain PD-L1+ cancer cells (Table 1). 
 
Comparison of tumors with or without PD-L1+ TILs  
Tumors containing PD-L1+-TILs (n=116) were compared to those without detectable 
TIL-PD-L1 expression (n=52) in terms of clinicopathological findings (Table 2). Both 
groups were similarly distributed with respect to tumor stage (p=0.128), lymph node 
status (p=0.396), histologic grading (p=1), or Siewert classification (p=0.252) (Table 
2). The number of patients who received neoadjuvant therapy was also similar in both 
groups (45/116 (38.8%) vs. 18/52 (34.6%), p=0.730, Table 2). However, TIL-PD-1 
expression patterns were significantly different in both groups (p=0.034, Table 2). 
Tumors lacking PD-1+ TILs (32/168, 19.1%) were PD-L1+ in 75% (24/32) and PD-L1- 
in 25% (8/32) of cases (Table 2). Conversely, 67.7% (92/136) of tumors containing PD-
1+ TILs (136/169, 80.9%) also harbored PD-L1+ TILs (Table 2). 
 
Correlation of PD-L1 expression by cancer cells and TILs with OS and DFS  
To evaluate the impact of PD-L1+ cancer cells and TILs on OS and DFS, PD-L1 
expression patterns were grouped into three subcategories: 0 (0%, PD-L1-), 1 (1-25%, 
PD-L1+) and 2+ (26-100%, PD-L1++), respectively. DFS increased significantly with an 
increase in PD-L1 expression by cancer cells (DFS: p=0.027, one-, 3- and 5-year DFS 
rates: cancer cell-PD-L1++ 89%, 77%, 77%; cancer cell-PD-L1+ 72%, 49%, 37%; 
cancer cell-PD-L1- 59%, 39%, 31%, respectively, Figure 2a). Additionally, OS was 
significantly higher in patients with higher cancer cell-PD-L1 expression (OS: p=0.045, 
one-, 3- and 5-year OS rates: cancer cell-PD-L1++ 95%, 76%, 76%; cancer cell-PD-
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L1+ 87%, 55%, 39%; cancer cell-PD-L1- 68%, 45%, 36%, respectively, Figure 2b). The 
comparison of DFS and OS between PD-L1++, PD-L1+ and PD-L1- expression by TILs 
did not reveal statistically significant differences (DFS: p=0.456, one-, 3- and 5-year 
DFS rates: TILs-PD-L1++ 63%, 55%, 50%; TILs-PD-L1+ 78%, 54%, 42%; TILs-PD-L1- 
54%, 32%, 29%, respectively, Figure 3a; OS: p=0.531, one-, 3- and 5-year OS rates: 
TILs-PD-L1++ 88%, 50%, 45%; TILs-PD-L1+ 84%, 62%, 45%; TILs-PD-L1- 59%, 40%, 
37%, respectively; Figure 3b).  
 
Association of clinicopathological parameters with OS and DFS as determined 
by univariate and multivariate cox regression analysis 
By univariate analysis, tumor size, lymph node status, grading, tumor stage, PD-L1 
expression by cancer cells, and PD-1 expression by cancer cells and TILs showed 
significant associations with OS and DFS (Table 3). No influence on OS and DFS was 
detected for PD-L1 expression by TILs (Table 3). The time period of resection as a 
potential impacting factor on OS or DFS was excluded by including it in univariate and 
multivariate analysis as a continuous and a grouped variable.  
By multivariate analysis, high PD-L1 expression by cancer cells proved to be an 
independent prognosticator of both DFS and OS (DFS: Hazard ratio (HR): 0.76, 
95%CI: 0.58-0.98, p=0.038; OS: HR: 0.75, 95%CI: 0.57-0.99, p=0.042, respectively, 
Table 3). Patients with positive lymph node status showed a significantly increased risk 
for disease progression (HR: 1.69, 95% CI 1.37-2.08, p<0.001) and death (HR: 1.66, 
95% CI 1.34-2.06, p<0.0019) (Table 3). Tumor size was only found to significantly 
affect DFS (HR: 1.5, 95% CI 1.08-2.09, p=0.016), but not OS (p=0.077), by multivariate 
analysis (Table 3).   
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Discussion 
 
In this study we evaluated the expression of PD-L1, PD-L2 and PD-1 and its potential 
clinical relevance in a comparatively large cohort of patients with esophageal and 
gastroesophageal junctional adenocarcinomas. Protein-expression of PD-L1, PD-L2 
and PD-1 were quantitated for both cancer cells and TILs. 8,25,26 PD-L1 expression by 
esophageal cancer cells was found in 43.5% (73/168) of patients and PD-L1 
expression by TILs was detected in 69% (116/168) of patients. These findings are in 
line with a recently published meta-analysis reporting PD-L1 positivity in around 50% 
of gastrointestinal tract cancers. 27 Increased expression of PD-L1 by cancer cells was 
found to be an independent factor of favorable outcome in our patient cohort, as 
determined by multivariate analysis. Additionally, 77.4% (130/168) of tumors were 
cancer cell-PD-1+ and 81% (136/168) contained PD-1+ TILs. We previously reported 
that expression of the PD-1 receptor by both cancer cells and TILs is associated with 
advanced tumor stage in esophageal adenocarcinoma. 28 Increased expression of PD-
1 was found to correlate with higher tumor stage and lymph node involvement. 
Although it was not found to be an independent predictor of outcome, TIL-PD-1+ and 
cancer cell-PD-1+ patients demonstrated significantly reduced DFS rates, as 
determined by univariate analyses. Interestingly, cancer cell-PD-1+ patients 
additionally showed decreased OS by univariate analysis. In the current study, we 
found that cancer cell-PD-L1+ patients show both improved DFS and prolonged OS, 
determined by multivariate analysis. Consistent with these opposing findings of PD-1 
vs. PD-L1 expression with DFS and OS, we further described in this study that a high 
number of cancer cell-PD-1- (38/168, 22.6%) and TILs-PD-1- (32/168, 19.1%) tumors 
demonstrated high expression of PD-L1 on both cancer cells (24/38, 63.2%) and TILs 
(24/32, 75%). The fact that high levels of an immune escape mechanism, PD-L1, 
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correlate with favorable clinical outcome is opposite of what one might have 
anticipated. One possible explanation for this finding could be that an inflamed tumor 
microenvironment containing high levels of T-effector cell infiltrates and inflammatory 
cytokines, including interferons (IFNs), could result in elevated expression levels of the 
IFN target gene, PD-L1. 8 29 PD-L1 might be up regulated after induction of immune 
responses leading to proliferation of T-cells and subsequently secretion of anti-tumoral 
cytokines such as IL-10 or interferon-γ. 20 30 Additionally, CD8+ T-cells and various 
other cytokines present in the tumor microenvironment (e.g. IL-2, interferon-γ, IL-7, IL-
15 and IL-21) can promote the expression of PD-L1. 31 32 33 PD-L1 expression may 
thus not necessarily coincide with an immunosuppressed microenvironment per se, 
but rather serve as a proxy for immune activation. Therefore, increased PD-L1 
expression might result from an adaptive immunological tumor-host relationship. 34 8 
Consistently, localized PD-L1 expression has been shown to advocate organ-specific 
autoimmunity. 35 On the other side, other receptors as for example B7-1 (CD80) have 
been described to interact with PD-L1 and might lead to bidirectional inhibitory 
responses in T cells. 36,37 
Consistent with this possibility and the findings reported herein, a correlation of PD-L1 
expression with positive prognosis has recently also been described in a study 
involving immunohistochemical analysis of tissue microarrays of 177 patients with 
advanced esophageal squamous cell carcinoma (ESCC). 38 Additionally, Jesinghaus 
and colleagues recently reported a significant association of high PD-L1 expression by 
cancer cells with improved OS and DFS in patients with ESCC. 34 They evaluated PD-
1 and PD-L1 expression immunohistochemically in 125 therapy-naïve ESCC patients 
and demonstrated a relationship between the presence of intraepithelial CD3+ TILs 
and high PD-L1 expression. 34 In a separate study 39 assessing PD-1 and PD-L1 
expression in tumor specimens from 349 patients with ESCC, increased PD-L1 
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expression was similarly found to significantly correlate with favorable clinical outcome. 
39 Although this stands in contrast to other studies reporting a less favorable outcome 
for PD-L1 positive ESCC, 18 19 20 21 22 a beneficial outcome of PD-L1 expression has 
also been described for various additional tumor entities, such as non-small cell lung 
cancer, colorectal carcinoma, melanoma, or Merkel cell carcinoma. 40 41 8 42 Another 
study investigating PD-L1 pathway member expression in a tissue microarray of 464 
patients with gastric adenocarcinoma found a significant correlation of both, PD-L1 and 
PD-1 with adverse prognostic pathological factors and OS. 43 The fact that in our cohort 
a PD-1+ PD-L1- expression pattern is associated with an unfavorable patient prognosis, 
could potentially relate to the possibility that PD-1 receptor expression by cancer cells 
may promote cancer progression by triggering tumor cell-intrinsic growth signals, a 
mechanism previously reported in melanoma. 44 
Most studies evaluating the PD-1 pathway in esophageal carcinoma have been 
performed in patients with ESCC, whereas its role in esophageal adenocarcinoma is 
poorly understood. Derks and colleagues assessed PD-1 pathway member expression 
in tissue microarrays of 354 patients with esophageal adenocarcinoma. 45 This group 
reported an association of PD-L2 expression with Barretts’s esophagus and 
furthermore described a potential association of the inflammatory environment in 
Barretts’s esophagus and PD-1 ligand expression. 45 In our study, PD-L2 was only 
occasionally expressed on cancer cells or TILs (3.5% and 1.8%, respectively). Indeed, 
PD-L2 has mainly been reported in macrophages and antigen-presenting cells. 
Nevertheless, some solid cancers, such as hepatocellular and endometrial carcinoma, 
have also shown cancer cell expression of PD-L2. 46-48 The relative rarity of PD-L2 in 
our patient cohort makes it difficult to estimate its potential clinicopathological impact 
or tumor immuno-biological significance in esophageal adenocarcinoma. The fact that 
the immunohistochemistry for PD-L2 is not as well established when compared to 
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immunohistochemistry with PD-L1 might explain differences in studies and a limited 
significance of PD-L2 expression in patients with AEG. 
To our knowledge, this represents one of the largest studies evaluating PD-1, PD-L1, 
and PD-L2 expression patterns in esophageal adenocarcinoma. Our study revealed, 
that expression of PD-L1 by cancer cells and by TILs is an independent predictor of 
improved DFS and OS in patients with esophageal adenocarcinoma. On the other side, 
PD-L2 expression was only rarely detected in our patient cohort. Additionally, we could 
describe that TIL-PD-1+ and cancer cell-PD-1+ patients demonstrated significantly 
reduced DFS rate in univariate analysis. Together, these findings highlight the potential 
importance of the PD-1 pathway in AEG development and underline the potential 
promise of PD-1 therapies for this devastating malignancy.   
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Figure legends 
 
Figure 1. This figure depicts representative images for (a) negative (0) PD-L1 staining 
on cancer cells, (b) 2+ and (c) 3+ positive PD-L1 staining on cancer cells as well as (d) 
negative (0) PD-L1 staining by TILs (e), 2+, and (f) 3+ positive PD-L1 staining by TILs.  
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Figure 2. Influence of PD-L1 expression by cancer cells on a) Disease free survival 
(DFS) and b) overall survival (OS). Patients were grouped in three categories 
according to the PD-L1 expression levels by cancer cells: 0 (0%, black line), 1 (1-25%, 
dark grey dotted line) and 2+ (26-100%, light grey dotted line). Patients at risk for each 
category and time point are summarized in the table blow the graph. 
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Figure 3. Influence of PD-L1 expression by TILs on a) Disease free survival (DFS) and 
b) overall survival (OS) Patients were grouped in three categories according to the PD-
L1 expression levels by TILs: 0 (0%, black line), 1 (1-25%, dark grey dotted line) and 
2+ (26-100%, light grey dotted line). Patients at risk for each category and time point 
are summarized in the table blow the graph. 
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Table 1.  PD-L1 expression by cancer cells in 168 patients with esophageal adenocarcinoma and its association with different clinicopathological findings 
  Adenocarcinoma (n=168) n (%) PD-L1+ cancer cells (n= 73) n 
(%) 
PD-L1- cancer 
cells (n=95) n 
(%) 
p-value 
Tumor size High-grade dysplasia 4 (2.4) 2 (2.7) 2 (2.1) 0.045 pT1a 13 (7.7) 8 (11) 5 (5.3)  pT1b 20 (11.9) 13 (17.8) 7 (7.4)  pT2 49 (29.2) 14 (19.2) 35 (36.8)  pT3 77 (45.8) 33 (45.2) 44 (46.3)  pT4 5 (3) 3 (4.1) 2 (2.1)  
Lymph node status pNx 13 (7.7) 8 (11) 5 (5.3) 0.520 pN0 61 (36.3) 29 (39.7) 32 (33.7)  pN1 31 (18.5) 11 (15.1) 20 (21)  pN2 26 (15.5) 10 (13.7) 16 (16.8)  pN3 37 (22) 15 (20.5) 22 (23.2)  
Histologic grading G1 7 (4.2) 3 (4.1) 4 (4.2) 0.584 G2 74 (44) 29 (39.7) 45 (47.4)  G3 87 (51.8) 41 (56.2) 46 (48.4)  
Neoadjuvant therapy No 105 (62.5) 47 (64.4) 58 (61) 0.748 Yes 63 (37.5) 26 (35.6) 37 (39)  
Total resection Yes 145 (86.3) 62 (84.9) 83 (87.4) 0.658 No 23 (13.7) 11 (15.1) 12 (12.6)  
Siewert classification AEG1 101 (60.1) 45 (61.6) 56 (58.9) 0.072 AEG2 44 (26.2) 14 (19.2) 30 (31.6)  AEG3 23 (13.7) 14 (19.2) 9 (9.5)  
PD1 expression by tumor cells 0 (0%) 38 (22.6) 24 (32.9) 14 (14.7) 0.016 1+ (1-25%) 36 (21.4) 11 (15.1) 25 (26.3)  2+ (26-50%) 30 (17.9) 8 (11) 22 (23.2)  3+ (51-75%) 43 (25.6) 20 (27.4) 23 (24.2)  4+ (76-100%) 21 (12.5) 10 (13.7) 11 (11.6)  
PDL1 expression by tumor cells 0 (0%) 95 (56.5)    1+ (1-25%) 51 (30.4)    2+ (26-50%) 12 (7.1)    3+ (51-75%) 8 (4.8)    4+ (76-100%) 2 (1.2)     
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Table 2.  PD-L1 expression by tumor infiltration lymphocytes (TILs) in 168 patients with esophageal adenocarcinoma and its association with different clinicopathological findings 
 
 
Adenocarcinoma 
(n=168) n (%) 
PD-L1+ TILs 
(n=116) n (%) 
PD-L1- TILs 
(n=52) n (%) 
p-value 
Tumor size High-grade dysplasia 4 (2.4) 4 (3.4) 0 0.128 pT1a 13 (7.7) 8 (6.9) 5 (9.6)  pT1b 20 (11.9) 17 (14.7) 3 (5.8)  pT2 49 (29.2) 28 (24.1) 21 (40.4)t  pT3 77 (45.8) 56 (48.3) 21 (40.4)  pT4 5 (3) 3 (2.6) 2 (3.8)  
Lymph node status pNx 13 (7.7) 11 (9.5) 2 (3.8) 0.396 pN0 61 (36.3) 43 (37) 18 (34.6)  pN1 31 (18.5) 22 (19) 9 (17.3)  pN2 26 (15.5) 19 (16.4) 7 (13.5)  pN3 37 (22) 21 (18.1) 16 (30.8)  
Histologic grading G1 7 (4.2) 5 (4.3) 2 (3.8) 1 G2 74 (44) 51 (44) 23 (44.2)  G3 87 (51.8) 60 (51.7) 27 (51.9)  
Neoadjuvant therapy No 105 (62.5) 71 (61.2) 34 (65.4) 0.730 Yes 63 (37.5) 45 (38.8) 18 (34.6)  
Total resection Yes 145 (86.3) 99 (85.3) 46 (88.5) 0.809 No 23 (13.7) 17 (14.7) 6 (11.5)  
Siewert classification AEG1 101 (60.1) 73 (62.9) 28 (53.8) 0.252 AEG2 44 (26.2) 26 (22.4) 18 (34.6)  AEG3 23 (13.7) 17 (14.7) 6 (11.5)  
PD1 expression by TILs 0 (0%) 32 (19.1) 24 (20.7) 8 (15.4) 0.034 1+ (1-25%) 56 (33.3) 31 (26.7) 25 (48.1)  2+ (26-50%) 68 (40.5) 50 (43.1) 18 (34.6)  3+ (51-75%) 12 (7.1) 11 (9.5) 1 (1.9)  4+ (76-100%) 0 0 0  
PDL1 expression by TILs 0 (0%) 52 (31)    1+ (1-25%) 77 (45.8)    2+ (26-50%) 29 (17.3)    3+ (51-75%) 10 (6)    4+ (76-100%) 0    
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Table 3. Influence of clinicopathological findings on overall survival (OS) and disease free survival (DFS) analysed by univariate and multivariate cox regression.  Footnote: CI (confidence interval), HR (Hazard ratio)  
 univariate  multivariate  
 HR CI p-value  HR CI p-value 
OS        pT 1.85 1.40-2.45 <0.001  1.36 0.97-1.91 0.077 pN  1.79 1.48-2.16 <0.001  1.66 1.34-2.06 <0.001 Grading  1.83 1.23-2.72 0.003     Tumor stage 1,33 1.20-1.48 <0.001     PD-L1 expression by cancer cells 0.75 0.57-0.99 0.045  0.75 0.57-0.99 0.042 PD-L1 expression by TILs 0.91 0.69-1.21 0.531     PD1 expression by cancer cells 1.28 1.09-1.51 0.003  1.09 0.86-1.39 0.484 PD1 expression by TILs  1.32 1.04-1.69 0.025  0.97 0.69-1.38 0.875         
DFS        pT 1.93 1.47-2.54 <0.001  1.50 1.08-2.09 0.016 pN 1.80 1.50-2.16 <0.001  1.69 1.37-2.08 <0.001 Grading  1.84 1.25-2.71 0.002     Tumor stage 1,40 1.26-1.55 <0.001     PD-L1 expression by cancer cells 0.74 0.56-0,97 0.027  0.76 0.58-0.98 0.038 PD-L1 expression by TILs 0.90 0.68-1.19 0.456     PD1 expression by tumor cells 1.20 1.03-1.40 0.022  0.91 0.73-1.14 0.411 PD1 expression by TILs 1.36 1.07-1.72 0.012  1.14 0.82-1.60 0.440  
 
